Clear Search

Showing 1 result for “Roden M”.

March 2022

Effects of Empagliflozin on Markers of Liver Steatosis and Fibrosis and Their Relationship to Cardiorenal Outcomes

Diabetes Obes Metab 2022; doi:10.1111/dom.14670

In this study of adults with T2D and established CV disease, the proportion of patients at high steatosis risk decreased slightly in patients treated with empagliflozin compared with patients treated with placebo. Fibrosis risk was not reduced.

more…